|
[1]MANCUSO L, SCORDATO F, PIERI M, et al.Management of portopulmonary hypertension:New perspectives[J].World J Gastroenterol, 2013, 19 (45) :8252-8257.
|
|
[2] ALDENKORTT F, ALDENKORTT M, CAVIEZEL L, et al.Portopulmonary hypertension and hepatopulmonary syndrome[J].World J Gastroenterol, 2014, 363 (25) :8072-8081.
|
|
[3]KROWKA MJ, SWANSON KL, FRANTZ RP, et al.Portopulmonary hypertension:Results from a 10-year screening algorithm[J].Hepatology, 2006, 44 (6) :1502.
|
|
[4]MICHELAKIS ED, WILKINS MR, RABINOVITCH M.Emerging concepts and translational priorities in pulmonary arterial hypertension[J].Circulation, 2008, 118 (14) :1486-1495.
|
|
[5]ALDENKORTT F, ALDENKORTT M, CAVIEZEL L, et al.Portopulmonary hypertension and hepatopulmonary syndrome[J].World J Gastroenterol, 2014, 363 (25) :8072-8081.
|
|
[6]DUBROCK HM, RODRIGUEZ-LOPEZ JM, LEVARGE BL, et al.Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension[J].Pulm Circ, 2016, 6 (4) :498.
|
|
[7]COLLE IO, MOREAU R, GODINHO E, et al.Diagnosis of portopulmonary hypertension in candidates for liver transplantation:A prospective study[J].Hepatology, 2003, 37 (2) :401-409.
|
|
[8]SHI LN, YU CC, CHENG J, et al.Transcranial Doppler ultrasound foaming test (C-TCD) in the screening of cryptogenic stroke complicated with patent foramen ovale (PFO) [J].J Apoplexy Nerv Dis, 2017, 34 (1) :48-50. (in Chinese) 史丽娜, 于成超, 成江, 等.经颅多普勒发泡实验在筛查隐源性卒中合并卵圆孔未闭的应用价值[J].中风与神经疾病杂志, 2017, 34 (1) :48-50.
|
|
[9]LIBERAL R, GRANT CR, BAPTISTA R, et al.Porto-pulmonary hypertension:A comprehensive review[J].Clin Res Hepatol Gastroenterol, 2015, 39 (2) :157-167.
|
|
[10]LIU YJ, LI T.An excerpt of International Liver Transplant Society practice guidelines:Diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension (2016) [J].J Clin Hepatol, 2016, 32 (10) :1838-1842. (in Chinese) 刘以俊, 李涛.《2016年国际肝移植学会实践指南:肝肺综合征与门脉性肺动脉高压的诊断与管理》摘译[J].临床肝胆病杂志, 2016, 32 (10) :1838-1842.
|
|
[11]OGIHARA Y, YAMADA N, DOHI K, et al.Effects of low-dose tolvaptan on electrolyte abnormality and hemodynamic parameters in a liver cirrhosis-associated portopulmonary hypertension patient:Acase report[J].Exp Ther Med, 2017, 13 (1) :269-272.
|
|
[12]MARON BA, OPOTOWSKY AR, LANDZBERG MJ, et al.Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure:A pilot study[J].Eur J Heart Fail, 2013, 15 (3) :277-283.
|
|
[13]PRESTON IR, SAGLIANI KD, WARBURTON RR, et al.Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension[J].Am J Physiol Lung Cell Mol Physiol, 2013, 304 (10) :L678-L688.
|
|
[14]SAVALE L, SATTLER C, COILLY A, et al.Long term outcome in liver transplantation candidates with portopulmonary hypertension[J].Hepatology, 2017, 64 (2) :1683-1692.
|
DownLoad: